Human Immunology News 6.28 July 17, 2018 | |
| |
TOP STORYReprogramming Human T Cell Function and Specificity with Non-Viral Genome Targeting Scientists developed a CRISPR-Cas9 genome-targeting system that does not require viral vectors, allowing rapid and efficient insertion of large DNA sequences at specific sites in the genomes of primary human T cells, while preserving cell viability and function. [Nature] Abstract | Press Release 1 | Press Release 2 | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Adjustment of Dendritic Cells to the Breast-Cancer Microenvironment Is Subset Specific Investigators used RNA-based next-generation sequencing to systematically analyze the transcriptomes of plasmacytoid pre-dendritic cells (DCs), cell populations enriched for type 1 conventional DCs, type 2 conventional DCs, CD14+ DCs and monocytes-macrophages from human primary luminal breast cancer and triple-negative breast cancer. [Nat Immunol] Abstract Researchers showed that the nonstimulatory, HIV-derived peptide GAG enhances a specific human cytotoxic T lymphocyte response to HBV-derived epitopes presented by HLA-A*02:01. [Nat Commun] Full Article Co-Expression of CD39 and CD103 Identifies Tumor-Reactive CD8 T Cells in Human Solid Tumors Researchers showed that CD103+CD39+ tumor-infiltrating CD8 T cells (CD8 TIL) were enriched for tumor-reactive cells both in primary and metastatic tumors. This CD8 TIL subset was found across six different malignancies and displayed an exhausted tissue-resident memory phenotype. [Nat Commun] Abstract Suppression of T cell function was blocked by anti-high-mobility group box 1 (HMGB1) antibody or the anti-inflammatory Box A domain of HMGB1. CD52-Fc induced tyrosine phosphorylation of Siglec-10 and was recovered from T cells complexed with HMGB1 and Siglec-10 in association with SHP1 phosphatase and the T cell receptor. [Proc Natl Acad Sci USA] Full Article The authors assessed frequency and diversity of leukemia-associated antigen-specific cytotoxic T cells using ELISpot and pMHC multimer assays and analyzed the frequency of regulatory T cells as well as cytokine profiles before/after donor lymphocyte infusions. [Int J Cancer] Abstract Scientists analyzed the capacity of peripheral blood effector T cells isolated both from patients with type 1 diabetes and from prediabetic at-risk subjects positive for multiple diabetes-associated autoantibodies to be suppressed by regulatory T cells. [J Immunol] Abstract The authors found was that increasing frequencies of tet+ CD8+ T cells in patients’ circulation correlated with increased frequencies of inactive naïve tet+ cells, while those with effector memory and terminally differentiated phenotypes, which are associated with positive anti-tumor immune responses, decreased. [Sci Rep] Full Article Scientists established a high-throughput screening workflow to systematically identify genes that impact the uptake of DiI-labeled low-density lipoprotein into monocyte-derived primary human macrophages. [Sci Rep] Full Article Investigators demonstrated that Vγ9γδT cells, innate immune cells activated by zoledronate, and Vα24NKT cells, innate/adaptive immune cells activated by α-galactosylceramide can link innate and adaptive immunities through cross talk with IFN-dendritic cells from patients with glioblastoma multiforme and healthy donors in a way that can amplify the activation and proliferation of CMVpp65-specific CD8+ T cells. [Clin Exp Immunol] Abstract Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWST Cell Senescence and CAR-T Cell Exhaustion in Hematological Malignancies The authors describe recent progress for restoration of T cell homeostasis from age-related senescence as well as recovery of T cell activation in hematological malignancies. [J Hematol Oncol] Full Article Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSGenmab A/S announced that it has entered into a research collaboration and exclusive license agreement with privately owned Immatics Biotechnologies GmbH, to discover and develop next-generation bispecific immunotherapies to target multiple cancer indications. [Genmab A/S] Press Release Cue Biopharma, Inc. announced progress in its ongoing strategic collaboration with Merck to develop Immuno-STATsâ„¢ for treating particular autoimmune diseases. [Cue Biopharma, Inc.] Press Release Eureka Therapeutics Inc. announced that Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCRm antibodies against an undisclosed target to be used for the potential development and commercialization of therapies for cancer patients. [Eureka Therapeutics Inc.] Press Release | |
| |
POLICY NEWSScience Journals End Open-Access Trial with Gates Foundation The publisher of Science ended a pilot partnership that allowed open-access (OA) publishing for researchers funded by the Bill & Melinda Gates Foundation. The trial was an effort to accommodate a policy clash between the Gates Foundation, which has enforced strict OA demands since 2017, and publishers that run subscription journals which don’t comply with those terms. [Nature News] Editorial Researchers Celebrate Rejection of Controversial Copyright Policy Early-career researchers are pleased at European leaders’ rejection of a copyright policy that would have introduced restrictions to text-and-data mining of scientific papers. [Chemistry World] Editorial
| |
EVENTSNEW Immuno-Oncology Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Postdoctoral Fellow – Immunotherapy (California Institute for Biomedical Research) Professorship – Molecular Immune Regulation (Kiel University) PhD Student – Cellular Immunotherapy (Glycostem Therapeutics) Postdoctoral Fellow – Immunoengineering for Muscle Regeneration (Duke University) Scientist/Senior Scientist – Lentivirus Production (Obsidian Therapeutics) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|